Select therapeutic use:

Breast cancer:

Indications for Cyclophosphamide Injection:

Carcinoma of the breast.

Adult:

Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.

Children:

See full labeling.

Contraindications:

Severe bone marrow depression.

Warnings/Precautions:

Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

See Also:

Pharmacologic Class:

Alkylating agent.

Interactions:

Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.

Adverse Reactions:

GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.

Note:

Formerly known under the brand name Cytoxan.

How Supplied:

Contact supplier

CNS cancers:

Indications for Cyclophosphamide Injection:

Neuroblastoma (disseminated disease).

Adult:

Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.

Children:

See full labeling.

Contraindications:

Severe bone marrow depression.

Warnings/Precautions:

Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

See Also:

Pharmacologic Class:

Alkylating agent.

Interactions:

Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.

Adverse Reactions:

GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.

Note:

Formerly known under the brand name Cytoxan.

How Supplied:

Contact supplier

Eye cancer:

Indications for Cyclophosphamide Injection:

Retinoblastoma.

Adult:

Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.

Children:

See full labeling.

Contraindications:

Severe bone marrow depression.

Warnings/Precautions:

Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

See Also:

Pharmacologic Class:

Alkylating agent.

Interactions:

Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.

Adverse Reactions:

GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.

Note:

Formerly known under the brand name Cytoxan.

How Supplied:

Contact supplier

Gynecologic cancers:

Indications for Cyclophosphamide Injection:

Adenocarcinoma of the ovary.

Adult:

Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.

Children:

See full labeling.

Contraindications:

Severe bone marrow depression.

Warnings/Precautions:

Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

See Also:

Pharmacologic Class:

Alkylating agent.

Interactions:

Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.

Adverse Reactions:

GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.

Note:

Formerly known under the brand name Cytoxan.

How Supplied:

Contact supplier

Leukemias, lymphomas, and other hematologic cancers:

Indications for Cyclophosphamide Injection:

Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma. Multiple myeloma. Leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease).

Adult:

Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.

Children:

See full labeling.

Contraindications:

Severe bone marrow depression.

Warnings/Precautions:

Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.

See Also:

Pharmacologic Class:

Alkylating agent.

Interactions:

Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.

Adverse Reactions:

GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.

Note:

Formerly known under the brand name Cytoxan.

How Supplied:

Contact supplier